IN recent years synthetic analogues of cortisone and hydrocortisone have been employed in the treatment of rheumatoid arthritis. Prednisone and prednisolone were first used by Bunim, Pechet, and Bollet in 1955, and since then further reports have followed (Dordick and Gluck, 1955; Margolis, Barr, Stolzer, Eisenbeis, and Martz, 1955; Hart, Clark, and Golding, 1955; Boland, 1956; and Montgomery, 1957) . Although the greater anti-rheumatic effects and lessened risks of sodium retention in these compounds have been advantageous, most workers have been concerned by the increased incidence of dyspepsia and gastro-(luodenal ulceration which attended their use. Because of this and other disadvantages, the search for newer compounds with fewer impleasant side-effects has continued, and recently two new steroids, triamcinolone and 6 -methyl prednisolone have been discovered. 6 -Methyl prednisolone (Medrone Upjohn), which is the subject of this report, is 6 -methyl -A 1 -hydrocortisone and differs from prednisolone only in the substitution of a methyl group for an H atom in the 6 alpha position.
By means of animal experiments Lyster et al. (1957) have shown it to be three times as potent as prednisolone using the glycogen deposition assay, and twice as potent in anti-inflammatory activity by the granuloma pouch assay. No measurable sodium or water retention was found;, and in fact, a sodium and water diuresis was observed in the experimental animal. 6 -Methyl predisolone has also been shown to be less susceptible to enzvmatic reduction bv the liver than prednisolone (Glen et al., 1957) .
In spite of these encouraging findings the earliest published report of the use of 6 -methyl prednisolone in rheumatoid arthritis was disappointing. Boland and Liddle (1957) trial. Case 4 developed an ischio-rectal abscess three months after the commencement of 6 -methyl prednisolone treatment. This was drained and while he was in hospital the opportunity was taken to repair an inguinal hernia. Both patients were given additional amounts of Medrone to cover the stress imposed by their surgical treatment, but as soon as possible the dose was reduced to the previous level. In theory both should have improved with the enhanced dosage of 6 -methyl prednisolone, but if the tables are perused it will be seen that their response was, in fact, the poorest in the series. It is likely, therefore, that the complications altered their physical condition and accounted, to some extent, for their indifferent progress. Strength of Grip.-An increase in strength was seen in all patients at the end of one week's treatment, and in five the improvement was considerable. After two months there were further gains in all but one (4) where the grip had weakened. When the dose of 6 -methyl prednisolone was reduced, strength of grip remained approximately the same in four patients but declined considerably in two (2 and 4) and to a lesser extent in one (7). Nevertheless, at the end of the trial, strength exceeded the initial reading in five patients, very slightly in one (2) and was worse only in one (4). Erythrocyte Sedimentation Rate.,-The E.S.R. altered very little during the trial. In three (5, 6, 7) it was reduced at the end of the study, in three (2, 3, 4) it was increased and in one (1) Side-effects of (6 -mtiethyl prednzisolonie treatmnent.-IBecause of their previous long-term steroid treatment all patients had already experienced some unpleasant side effects, and it was therefore difficult to know if 6 -methyl predcnisolone lessened or increased these complications. Peptic ulceration is the most important hazard of synthetic steroid treatment, and the reputation of any new compound will be largely determined by the frequency of this complication. A clinical trial in whichl 6 -methyl prednisoloeti was compared with prednisolone is described. Measurement of joint function was carriedl out at intervals to provide objective evidence of therapeutic response. 'Fhe drug is an effective suppressive agent for the treatment of rheumatoid arthritis and is slightly more powerful than prednisiolone. Side effects appeared to be similar to those occurring with prednisolone but facial rounding and flushing, and increases in weight were less pronounced. No opinion can be expressed about the effect of 6 -methyl prednisolone on gastro-duodenal function.
It is concluded that 6 -methyl prednisolone is aI useful new steroid, and if additional experience confirms that the increase in therapeutic efficiency is matched by a reduced incidence of unpleasant side-effects, then it will probably become the steroid of choice for the treatment of rheumatoid arthritis. 
